Company: TELO
Filing Date: 2025-10-20
Form Type: 8-K
Source: 0001493152-25-018634
Chunk: 1

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-10-20
Form: 8-K
Item: Item 1.01
Chunk 1
---
 simplifying global
development and partnership efforts. As a result of the Transaction, Telomir Pharmaceuticals will own the entire worldwide intellectual
property portfolio and development programs related to Telomir-1.

The
foregoing description of the LOI does not purport to be complete and is qualified in its entirety by reference to the full text of such
agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item
9.01. Financial Statements and Exhibits

(d)
Exhibits.

  Exhibit      Exhibit                                                                                                         
      No.      Description                                                                                                     
     10.1      Letter of Intent, dated October 17, 2025, between Telomir Pharmaceuticals, Inc. and TELI Pharmaceuticals, Inc.  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
      104      Cover Page Interactive                                                                                          

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                               TELOMIR PHARMACEUTICALS, INC.                               
  Dated: October 20, 2025      By:                                /s/                      
                               Name:                              Erez Aminov              
                               Title:                             Chief Executive Officer